Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands

por Xander, Nicolas S. H., Fiets, W. Edward, Uyl-de Groot, Carin A.
Publicado 2023

Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin...

por Ham, Janneke C., van Meerten, Esther, Fiets, W. Edward, Beerepoot, Laurens V., Jeurissen, Frank J. F., Slingerland, Marije, Jonker, Marianne A., Husson, Olga, van der Graaf, Winette T. A., van Herpen, Carla M. L.
Publicado 2020